← FDA DRUG APPROVALS

FDA NDA · NDA213224

BYNFEZIA PEN

octreotide acetate

Sponsor: SUN PHARM

APPLICATION
NDA213224
TYPE
NDA
ORIGINAL APPROVAL
2024-09-27
LATEST ACTION
2024-09-27
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

BYNFEZIA PEN · ReferencePrescription
OCTREOTIDE ACETATE EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML) · SOLUTION · SUBCUTANEOUS

Approval history

2024-09-27Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →